November 18, 2026
Pfizer Inc. (NYSE: PFE) does not need artificial intelligence to discover its patent cliff. The calendar has that covered. What the drugmaker needs is for newer medicines to grow fast enough to replace sales lost as older drugs face…
A Retinal Bet With Big-Pharma Muscle and Blackstone Financing
Johnson & Johnson (NYSE: JNJ) is putting substantial capital behind a straightforward proposition: better control of retinal disease, potentially with more time between treatments, would be worth bringing into its pharmaceutical portfolio. On…
A Precision-Oncology Bet With Room to Grow
Eli Lilly and Company (NYSE: LLY) is adding another potential growth engine to a business already well acquainted with acceleration. On November 16, Calytrix Bio announced a definitive agreement to be acquired by Lilly in…
AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst
Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth…
With oral VK2735 entering Phase 3 and injectable trials fully enrolled, Viking Therapeutics (NASDAQ: VKTX) is building a broader case in weight management.
Viking Therapeutics (NASDAQ: VKTX) has strengthened two foundations of its obesity-drug investment story: the capital to advance its programs…
Two new funds, institutional backing and a pharmaceutical heavyweight give the European life sciences investor fresh capital to turn promising science into investable businesses.
Biotechnology has never suffered from a shortage of ambitious ideas. Financing them is another matter. Forbion has just…
Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles.
The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…
The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…
Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…
Many entered the week bracing for a Federal Reserve rate hike, yet the more constructive takeaway may be that policy makers still have room to choose patience. That possibility, alongside fresh evidence of AI-led ecommerce change, government-scale digital-health demand and advancing biotech milestones,…
